BioCardia announced its Q3 2026 financial results, highlighting progress in its CardiAMP autologous cell therapy for heart failure, which is nearing regulatory approval in Japan and preparing for FDA submission. The company also advanced its Helix transendocardial delivery system, expecting FDA approval by mid-2027. Financially, BioCardia reported a net loss of $1.9 million for Q3 with cash reserves supporting operations into 2027. Upcoming milestones include CardiAMP submission in Japan, FDA feedback on Helix, and clinical advancements with Heart3D imaging and gene therapy partnerships.
BioCardia's Q3 2026 financial results come as Pluang's Health sector shows broad declines, with only 23 of 150 US stocks rising on the day. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: Butterfly Network Inc. (BFLY) fell 7.00% to USD 6.64 with a typical hold time of 17 days, Recursion Pharmaceuticals Inc. (RXRX) dropped 6.96% to USD 3.34 with balanced buy/sell order activity and a 23-day hold time, and Heron Therapeutics Inc. (HRTX) declined 6.90% to USD 0.33 with a 52% sell order activity and 39-day hold time.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
